Evidence map›Paper›PMID 34908460›Full record

ArticlemSphere2021

NanI Sialidase Enhances the Action of Clostridium perfringens Enterotoxin in the Presence of Mucus.

Mauricio A Navarro, Jihong Li, Juliann Beingesser, Bruce A McClane, Francisco A Uzal

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. The biology and pathogenicity ofMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  7. Isolation of a VirulentCurrent issues in molecular biology · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Mauricio A Navarro *California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California, Davisgrid.27860.3b, San Bernardino, California, USA.
Jihong Li *Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Juliann BeingesserCalifornia Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California, Davisgrid.27860.3b, San Bernardino, California, USA.
Bruce A McClaneDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-2451-5140
Francisco A UzalCalifornia Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California, Davisgrid.27860.3b, San Bernardino, California, USA.ORCID 0000-0003-0681-1878
California State University, San Bernardino · USUniversity of Pittsburgh · USAustral University of Chile · CL

Funding

NanI sialidase: Effects on Clostridium perfringens enterotoxin activity and contributions to C. perfringens type F infectionR21AI148911 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MC CLANE, BRUCE A, UZAL, FRANCISCO A · 2020 to 2021
$445k
Evaluating the Clostridium perfringens Agr-like Quorum Sensing System as a Therapeutic TargetR21AI140010 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MC CLANE, BRUCE A, UZAL, FRANCISCO A · 2018 to 2019
$445k
Pathogenic Contributions of Clostridium perfringens NanI SialidaseR21AI125796 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, JIHONG, MC CLANE, BRUCE A · 2016 to 2017
$402k
NIAID NIH HHS R21 AI125796NIAID NIH HHS R21 AI140010NIAID NIH HHS R21 AI148911
6 · The paper itself

Abstract

Clostridium perfringens enterotoxin (CPE) is the main virulence factor for C. perfringens type F strains to cause human gastrointestinal diseases, which can involve lethal enterotoxemia. During type F disease, CPE encounters an adherent mucus layer overlying the intestines, so the current study evaluated if NanI potentiates CPE activity in the presence of adherent mucus. CPE alone caused more cytotoxicity transepithelial electrical resistance (TEER) and permeability to fluorescent dextran (FD) for minimal mucus-producing HT29 cells versus that in their derivative HT29-MTX-E12 cells, which produce abundant adherent mucus. However, for HT29-MTX-E12 cells, the presence of NanI significantly increased CPE binding and pore formation, which enhanced their sensitivity to CPE effects on cytotoxicity, TEER, and FD permeability. When the ability of NanI to potentiate CPE-induced enterotoxemia was then tested in a mouse small intestinal loop enterotoxemia model, a pathophysiologically relevant 50 μg/mL dose of CPE did not kill mice. However, the copresence of purified NanI resulted in significant CPE-induced lethality. More CPE was detected in the sera of mice challenged with 50 μg/mL of CPE when NanI was copresent during challenge. The copresence of NanI and CPE during challenge also significantly increased intestinal histologic damage compared to that after challenge with CPE alone, suggesting that NanI enhancement of CPE-induced intestinal damage may increase CPE absorption into blood. Overall, these results indicate that (i) mucus inhibits CPE action and (ii) NanI can potentiate CPE action in the presence of mucus, which may help explain why type F strains that produce relatively low levels of CPE are still pathogenic.

Indexed as

AnimalsBacterial AdhesionCaco-2 CellsClostridium perfringensEnterotoxinsFemaleGene Expression Regulation, BacterialHT29 CellsHumansIntestinesMaleMiceMice, Inbred BALB CMucusNeuraminidaseVirulence Factorsenterotoxin, ClostridiumEnterotoxinsNeuraminidaseVirulence FactorsClostridium perfringensenterotoxinmucusNanI sialidase

Identifiers

PMID34908460
PMCPMC8673254
OpenAlexW4200250848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.